GlaxoSmithKline

Risks associated with omega-3 supplementation
Risks associated with omega-3 supplementationDuring my preoperative visit, my surgeon handed me a list of no less then 165 medications and supplements that I should stop taking 14 days prior to my surgery. Fish and krill oil were on the list, as were aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)—as expected.
Differentiating ocular allergyOn the surface, eyecare providers may not fully appreciate the prevalence and complexity of ocular allergy and its clinical management; we learn that it is a relatively simple disease defined by ocular itch.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
Pricing report blasts asthma drug costIn the latest controversy over drug pricing, an organization said that the price of GlaxoSmithKline’s Nucala (mepolizumab), an injectable indicated for severe asthma patients with eosinophilic inflammation, is far over-priced.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
First-in-class biologic maintenance therapy approved for severe asthmaFDA approved mepolizumab (Nucala) as an add-on maintenance therapy for the treatment of patients with severe asthma who are 12 years and older and with an eosinophilic phenotype.
FDA panel backs approval of GSK's mepolizumab for severe asthmaThe FDA’s Pulmonary-Allergy Drugs Advisory Committee recently recommended approval of GlaxoSmithKline Plc's drug mepolizumab (Nucala) for severe asthma patients 18 and older.
FDA follow-up confirms low risk of long-term vision loss secondary to ezogabine pigment changesFDA has issued a drug safety communication on GlaxoSmithKline's anti-seizure drug ezogabine (Potiga). Side effects of the the drug, which may include vision loss due to eye pigment change and skip discoloration, can be "adequately managed" by following the label, reports the FDA.
The 4 most problematic drug shortagesDrug shortages are significant public health threats. They can delay, or even deny, critical care for patients. Here are the four drugs in shortage that are among the most problematic.
FDA panels approve Breo Ellipta for asthma in adults, not kidsFood and Drug Administration (FDA) committees this week voted to approve GlaxoSmithKline and Theravance’s Breo ELlipta (fluticasone furoate/vilanterol) as an asthma treatment for adults 19 years and older, but not for 12 to 17-year-olds.